Drugs / Nanobody-Based CD19/CD22 Tandem Dual CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06880913 | Nov 2024 → Dec 2026 expected | precursor lymphoblastic lymphoma/leukemia | Peking University People's Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nanobody-Based CD19/CD22 Tandem Dual CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06880913 ↗ |
| Modality | Cell therapy | “Nanobody-Based CD19/CD22 Tandem Dual CAR-T-cell therapy” NCT06880913 ↗ |
| Route | Other | “single infusion of autologous CD19/CD22 dual CAR-T cells” NCT06880913 ↗ |
| Target | CD19 | “autologous CD19/CD22 dual CAR-T cells” NCT06880913 ↗ |
| Target | CD22 | “autologous CD19/CD22 dual CAR-T cells” NCT06880913 ↗ |